PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of advvirolJournal's HomeManuscript SubmissionAims and ScopeAuthor GuidelinesEditorial BoardHome
 
Adv Virol. 2012; 2012: 586389.
Published online Jul 24, 2011. doi:  10.1155/2012/586389
PMCID: PMC3265225
Oncolytic Viruses: The Power of Directed Evolution
Maxine Bauzon and Terry W. Hermiston *
Bayer Healthcare, Biologics Research, 455 Mission Bay Boulevard South, San Francisco, CA 94158, USA
*Terry W. Hermiston: terry.hermiston/at/bayer.com
Academic Editor: Nanhai G. Chen
Received April 26, 2011; Accepted May 26, 2011.
Abstract
Attempts at developing oncolytic viruses have been primarily based on rational design. However, this approach has been met with limited success. An alternative approach employs directed evolution as a means of producing highly selective and potent anticancer viruses. In this method, diverse viruses are grown under conditions that maximize diversity and then passaged under conditions meant to mimic those encountered in the human cancer microenvironment. Viruses which evolve to thrive under this selective pressure are isolated and tested to identify those with increased potency (i.e., ability to replicate and spread) and/or an increased therapeutic window (i.e., differentiated replication and spread on tumor versus normal cells), both of which have potential value but the latter of which defines an oncolytic virus. Using ColoAd1, an oncolytic virus derived by this approach as a prototype, we highlight the benefits of directed evolution, discuss methods to “arm” these novel viruses, and introduce techniques for their genetic modulation and control.
Articles from Advances in Virology are provided here courtesy of
Hindawi Publishing Corporation